Kymera Therapeutics, Inc. $KYMR Shares Acquired by Rafferty Asset Management LLC

Rafferty Asset Management LLC boosted its position in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 70.2% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 68,295 shares of the company’s stock after buying an additional 28,157 shares during the quarter. Rafferty Asset Management LLC owned 0.09% of Kymera Therapeutics worth $3,865,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Federated Hermes Inc. bought a new stake in shares of Kymera Therapeutics during the 3rd quarter worth $31,622,000. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Kymera Therapeutics by 77.2% during the second quarter. China Universal Asset Management Co. Ltd. now owns 23,079 shares of the company’s stock valued at $1,007,000 after purchasing an additional 10,052 shares during the last quarter. Candriam S.C.A. lifted its holdings in shares of Kymera Therapeutics by 24.4% during the third quarter. Candriam S.C.A. now owns 191,639 shares of the company’s stock valued at $10,847,000 after purchasing an additional 37,536 shares during the last quarter. Frontier Capital Management Co. LLC boosted its position in shares of Kymera Therapeutics by 272.7% in the 2nd quarter. Frontier Capital Management Co. LLC now owns 491,810 shares of the company’s stock valued at $21,463,000 after purchasing an additional 359,847 shares during the period. Finally, Universal Beteiligungs und Servicegesellschaft mbH increased its stake in Kymera Therapeutics by 26.3% in the 2nd quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 107,438 shares of the company’s stock worth $4,689,000 after purchasing an additional 22,392 shares in the last quarter.

Wall Street Analyst Weigh In

A number of analysts have commented on KYMR shares. Wall Street Zen raised shares of Kymera Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, November 8th. Bank of America upped their price target on shares of Kymera Therapeutics from $71.00 to $112.00 and gave the company a “buy” rating in a research report on Tuesday, December 9th. Mizuho raised their price objective on shares of Kymera Therapeutics from $81.00 to $120.00 and gave the stock an “outperform” rating in a research note on Thursday, December 11th. Royal Bank Of Canada reissued an “outperform” rating and set a $108.00 target price on shares of Kymera Therapeutics in a research note on Thursday, February 26th. Finally, Stephens increased their target price on Kymera Therapeutics from $95.00 to $100.00 and gave the company an “overweight” rating in a report on Monday. One analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $119.50.

Kymera Therapeutics Stock Performance

Kymera Therapeutics stock opened at $86.35 on Wednesday. The firm has a market cap of $7.05 billion, a PE ratio of -23.46 and a beta of 2.20. The firm’s 50 day moving average price is $78.69 and its two-hundred day moving average price is $66.27. Kymera Therapeutics, Inc. has a twelve month low of $19.44 and a twelve month high of $103.00.

Kymera Therapeutics (NASDAQ:KYMR) last issued its earnings results on Thursday, February 26th. The company reported ($0.97) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.77) by ($0.20). Kymera Therapeutics had a negative net margin of 794.04% and a negative return on equity of 28.71%. The company had revenue of $2.87 million for the quarter, compared to analyst estimates of $14.80 million. During the same period last year, the business earned ($0.88) EPS. The company’s quarterly revenue was down 60.8% on a year-over-year basis. Equities analysts anticipate that Kymera Therapeutics, Inc. will post -2.79 EPS for the current fiscal year.

Insider Activity

In other Kymera Therapeutics news, CEO Nello Mainolfi sold 30,000 shares of the business’s stock in a transaction dated Wednesday, February 25th. The stock was sold at an average price of $90.26, for a total value of $2,707,800.00. Following the transaction, the chief executive officer owned 666,195 shares in the company, valued at $60,130,760.70. The trade was a 4.31% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Bruce Booth sold 678 shares of the firm’s stock in a transaction dated Friday, December 12th. The stock was sold at an average price of $91.04, for a total value of $61,725.12. Following the sale, the director directly owned 685,393 shares of the company’s stock, valued at $62,398,178.72. This trade represents a 0.10% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 450,895 shares of company stock valued at $40,486,151. 16.01% of the stock is currently owned by company insiders.

Kymera Therapeutics Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.